CSL Ltd (ASX: CSL) shares are enjoying a welcome day of outperformance today.

Shares in the S&P/ASX 200 Index (ASX: XJO) biotech giant closed yesterday trading for $112.88. In morning trade on Tuesday, shares are changing hands for $113.38, up 0.4%.

For some context, the ASX 200 is down 0.1% at this same time.

I mention today’s outperformance as ‘welcome’ because, longer term, the ASX healthcare share has been having a tough time of it.

How tough?

Well, despite today’s uptick, shares remain down a steep 52.9% over the past 12 months. A capital loss that will have only been very modestly eased by the two unfranked dividends the company paid out to eligible stockholders over the last year.

CSL shares trade on a 3.8% unfranked trailing dividend yield.

And if Peak Asset Management’s Niv Dagan has it right, the Aussie biotech company isn’t out of the woods just yet (courtesy of The Bull).

Here’s why.

Time to sell CSL shares?

“A sell rating is justified as this biotechnology giant has materially downgraded its fiscal year 2026 outlook while announcing about $5 billion of additional non-cash pre-tax impairments across fiscal years 2026 and 2027,” Dagan noted.

“Revenue expectations have been reduced due to US immunoglobulin channel normalisation and weaker albumin prices in China,” he added.

Summarising his other potential headwinds facing CSL shares, Dagan concluded:

The CSL Vifor acquisition has under-performed. Also, government healthcare cost pressures and a higher interest rate environment present ongoing challenges for the biotechnology sector, further weighing on sentiment.

What did the ASX 200 healthcare share report?

CSL shares closed down a precipitous 16% on 11 May, the day the company reported on the downgraded FY 2026 outlook Dagan mentioned above.

Investors were overheating their sell buttons after the company cut its FY 2026 revenue guidance to around $15.2 billion, in constant currency. That would represent a 2.5% decline from FY 2025 revenue.

CSL also reduced its full-year net profit after tax and amortisation (NPATA) forecast to approximately $3.1 billion. That’s down 6% from the prior year.

Commenting on the revised forecasts on the day, CSL managing director and CEO Gordon Naylor said, “Our growth initiatives are working, but the financial benefits will take longer than previously anticipated to materialise.”

Naylor added:

As a result, we have now revised down our 2026 financial year guidance.

CSL’s culture and people continue to be first class, the industry is stable and growing, and the company has evident strengths in plasma collections and influenza vaccines. I am confident that the company can be returned to profitable growth and my work is to position the business and the next CEO for success.

The post Down 53%, is it time to throw in the towel on CSL shares? appeared first on The Motley Fool Australia.

More reading

• Should I buy CSL and ResMed shares right now?
• 3 reasons why experts think CSL shares are a sell
• 3 ASX healthcare shares to sell despite signs of sector rebound
• Buy, hold, sell: Life360, Woodside, CSL shares
• Why CSL, Westpac, and this big-name ASX 200 share could be sells

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

WiseTech Global Ltd (ASX: WTC) shares have rebounded strongly in early morning trade on Tuesday.

At the time of writing, WiseTech shares are up over 5% and changing hands for $31.60 a piece.

It’s good news for investors after the stock crashed around 18% to a five-year low on Monday.

It’s been a steep and sustained share price crash for WiseTech shares, driven mostly by a tech-sector-wide sell-off and an investor rotation to more stable assets amid global volatility earlier this year. 

Even after today’s increase, WiseTech shares are still down around 54% for the year to date. They’re also over 70% lower than this time last year.

What happened to WiseTech shares this week?

WiseTech shares fell sharply on Monday after media reports that the Australian Federal Police is investigating founder Richard White over alleged trafficking matters. The matters relate to a former cleaner at WiseTech.

It has been claimed that White exploited a former cleaner’s immigration status and financial position and provided false information on a visa application. 

Investors reacted quickly and rushed to the exits.

Why is the share price climbing higher again today?

In a note to the ASX ahead of the market open this morning, WiseTech has responded to the media reports.

WiseTech said that it notes there was media commentary yesterday alleging an investigation into Richard White, reportedly relating to a visa application. The company said:

The media reports that the alleged investigation relates to Richard White in a personal capacity. There is no suggestion in this media commentary of an investigation into WiseTech.

The Company is not aware of any investigation as outlined in the article. The Executive Chair has provided assurance to the Board that he is not aware of any such investigation and also confirmed that he emphatically and unequivocally denies any involvement in or with human trafficking.

The Company will keep the market updated in accordance with its continuous disclosure obligations.

It looks like the update has helped put investors at ease, and many are buying back into the technology company’s shares this morning.

Should investors buy in the dip or stay clear of WiseTech shares?

The outlook for WiseTech shares is largely unchanged at the time of writing. Brokers and analysts are still very bullish on where we’ll see the share price travel from here.

Market Index shows that the majority of brokers (six out of seven) are very bullish on the ASX tech stock and hold a strong buy rating. The average $72.39 target price implies a potential 130% upside over the next 12 months, at the time of writing.

TradingView data shows something similar. Out of 14 analysts, 11 have a buy or strong buy rating on WiseTech shares. Another three have a hold rating. 

Their average target price is a little lower, at $67.17, but that still implies a potential 113% upside, at the time of writing. The more bullish analysts are tipping an enormous 280% upside to a maximum target price of $119.62.

It looks like it’s time for investors to snap up the shares while they’re at a rock-bottom price.

The post WiseTech shares rebound 5%, responds to media reports: Is it time for investors to buy back in? appeared first on The Motley Fool Australia.

More reading

• WiseTech shares just crashed. Can investors look past the company’s governance issues?
• Why Humm, Metcash, PLS, and WiseTech shares are sinking today
• WiseTech shares crash 12% as founder scandal deepens
• Down but not out: 3 ASX tech shares ripe for a rebound
• Is the only way up for WiseTech shares after a 65% fall?

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Ioneer Ltd (ASX: INR) share price is having a strong day on Tuesday.

In morning trade, the ASX lithium share is up 25% to 17.5 cents.

Why is this ASX lithium share jumping?

Investors have been scrambling to buy the company’s shares today after it released a big update on its Rhyolite Ridge Lithium-Boron Project.

According to the release, the company has entered into strategic non-binding letters of intent (LOI) with the Korea Overseas Infrastructure & Urban Development Corporation and Hyundai Engineering Co.

The former is the Republic of Korea’s specialised public institution mandated by the Ministry of Land, Infrastructure and Transport (MOLIT) to facilitate and invest in overseas infrastructure and public-private partnership projects.

The latter is a leading Korean and international engineering, procurement, and construction company.

The LOI will see the parties work together to advance the development of the Rhyolite Ridge Lithium-Boron Project.

The ASX lithium share believes the project holds significant strategic value for both the Republic of Korea and the United States.

It notes that Rhyolite Ridge hosts the only known lithium-boron reserve in North America, one of two globally, and the only project of its kind in active development.

The parties intend to formalise their cooperation through the execution of Memorandums of Understanding, which are expected in July 2026.

Rhyolite Ridge Project

Ioneer reiterated that it is targeting a final investment decision for the second half of 2026, with first commercial production expected in 2029.

Once operational, Rhyolite Ridge will process ore into final products entirely on-site with annual lithium hydroxide and annual boric acid production of 27,800 tonnes per annum (tpa) and 135,500 tpa, respectively.

Commenting on the news, Ioneer’s managing director, Bernard Rowe, said:

Rhyolite Ridge has been a decade in the making — through ongoing partnerships, permitting, and financing. Working with trusted Korean partners with a track record of on-time and on-budget delivery brings us closer to breaking ground and delivering urgently needed lithium and boron.

We’re delighted to work with KIND and Hyundai Engineering and look forward to what we’ll accomplish together.

KIND’s director of plant business division, Chris Soeung Kim, spoke positively about the agreement, adding:

KIND, as a specialized PPP investment institution under the MOLIT, has been actively advancing investments in U.S. energy, infrastructure, and critical minerals projects. We view this project as a major milestone that will further strengthen bilateral cooperation and deepen the strategic partnership between the Republic of Korea and the United States.

The post Guess which ASX lithium share is jumping 15% on big news appeared first on The Motley Fool Australia.

More reading

• 3 companies to own for a dividend yield above 5%
• This ASX energy stock is sliding despite a major refinery restart
• $5,000 invested in BHP shares 12 months ago is now worth….
• Buy, hold, sell: Charter Hall, Northern Star, Cochlear shares
• Down 53%, is it time to throw in the towel on CSL shares?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.